RESUMEN
BACKGROUND: COVID-19 vaccines are highly immunogenic but cardiovascular effects of these vaccines have not been properly elucidated. OBJECTIVES: To determine impact of COVID-19 vaccination on mortality following acute myocardial infarction (AMI). METHODS: This was a single center retrospective observation study among patients with AMI enrolled in the the North India ST-Elevation Myocardial Infarction (NORIN-STEMI) registry. In all the enrolled patients, data regarding patient's vaccination status including details on type of vaccine, date of vaccination and adverse effects were obtained. All enrolled subjects were followed up for a period of six months. The primary outcome of the study was all-cause mortality both at one month and at six months of follow-up. Propensity-weighted score logistic regression model using inverse probability of treatment weighting was used to determine the impact of vaccination status on all-cause mortality. RESULTS: A total of 1578 subjects were enrolled in the study of whom 1086(68.8%) were vaccinated against COVID-19 while 492(31.2%) were unvaccinated. Analysis of the temporal trends of occurrence of AMI post vaccination did not show a specific clustering of AMI at any particular time. On 30-day follow-up, all-cause mortality occurred in 201(12.7%) patients with adjusted odds of mortality being significantly lower in vaccinated group (adjusted odds ratio[aOR]: 0.58, 95% CI: 0.47-0.71). Similarly, at six months of follow-up, vaccinated AMI group had lower odds of mortality(aOR: 0.54, 95% CI: 0.44 to 0.65) as compared to non-vaccinated group. CONCLUSIONS: COVID-19 vaccines have shown to decrease all-cause mortality at 30 days and six months following AMI.
Asunto(s)
COVID-19 , Infarto del Miocardio , Humanos , Vacunas contra la COVID-19/efectos adversos , Puntaje de Propensión , Estudios Retrospectivos , VacunaciónRESUMEN
OBJECTIVES: Currently, erythrocyte sedimentation rate (ESR) and highly sensitive serum C-reactive protein (hsCRP) levels are used to monitor disease activity and guide therapy in Takayasu Arteritis (TA). However, non-specificity of these markers suggests the need for novel biomarkers. In this pilot study, we explore the role of novel biomarkers for evaluating disease activity in TA. METHODS: A total of 40 patients with TA were divided into active and stable disease groups. Disease activity was assessed according to the National Institutes of Health criteria proposed by Kerr et al. Routine blood investigations were obtained and serum tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-18, ESR, hsCRP levels and NLR (neutrophil to lymphocyte ratio) were assayed at baseline and after 6 months. RESULTS: Among the 40 patients enrolled, 18 were classified as active while 22 were stable at baseline and with a similar pattern at 6 months. Along with ESR and hsCRP, IL-6 and IL-18 levels were significantly higher in the active disease group than in the stable disease group (p < 0.005). The levels of other novel biomarkers (IL-1, TNF-α) and NLR were not significantly higher in active disease group. CONCLUSION: Serum IL-6 and IL-18 levels correlates well with disease activity in TA which suggests their important role in disease pathogenesis and may be helpful in guiding and monitoring therapy in active TA patients.
Asunto(s)
Arteritis de Takayasu , Biomarcadores , Sedimentación Sanguínea , Proteína C-Reactiva , Humanos , Proyectos Piloto , Arteritis de Takayasu/diagnósticoAsunto(s)
Aneurisma/diagnóstico por imagen , Angiografía de Substracción Digital , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Arteritis de Takayasu/diagnóstico por imagen , Diagnóstico Diferencial , Femenino , Glucocorticoides/uso terapéutico , Humanos , Prednisolona/uso terapéutico , Arteritis de Takayasu/tratamiento farmacológico , Adulto JovenRESUMEN
Heart hand syndromes are characterized by radial abnormalities and associated defects in the heart. We here describe an extremely rare heart hand syndrome known as Baller-Gerold syndrome.